Market Snapshot
S&P Futures
4,276
Dow Futures
33,859
Nasdaq Futures
13,525
ERYTECH Pharma S.A. (ERYP) stock declined over -2.33% intraday to trade at $1.26 a share on NASDAQ. The stock opened with a loss of -1.56% at $1.32 and touched an intraday high of $1.472, falling -3.45% against the last close of $1.305. The stock went to a low of $1.29 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-08-17 | $1.32 | $1.472 | $1.29 | $1.31 | 58,105 |
2022-08-16 | $1.28 | $1.331 | $1.28 | $1.305 | 5,500 |
2022-08-15 | $1.2 | $1.3 | $1.2 | $1.28 | 5,800 |
2022-08-12 | $1.22 | $1.35 | $1.22 | $1.29 | 30,100 |
2022-08-11 | $1.15 | $1.28 | $1.091 | $1.21 | 23,000 |
2022-08-10 | $1.237 | $1.24 | $1.17 | $1.18 | 16,400 |
2022-08-09 | $1.2 | $1.26 | $1.17 | $1.17 | 34,800 |
2022-08-08 | $1.08 | $1.15 | $1.08 | $1.12 | 5,100 |
2022-08-05 | $1.16 | $1.16 | $1.1 | $1.1 | 9,200 |
2022-08-04 | $1.14 | $1.21 | $1.13 | $1.16 | 9,800 |
Employees-
Beta1.91
Sales or Revenue3.28 Million
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
ERYTECH Pharma S.A. (NASDAQ: ERYP) stock price is $1.26 as of the last check on Wednesday, August 17. During the trading session, ERYP stock reached the peak price of $1.472 while $1.29 was the lowest point it dropped to.
The NASDAQ listed ERYP is part of Biotechnology industry that operates in the broader Health Care sector. ERYTECH Pharma S. A.
Mr. Jean-Sebastien Cleiftie M.B.A., M.S.
Chief Bus. Officer
Mr. Eric Soyer Ph.D.
CFO, COO & Deputy GM
Dr. Stewart Craig
Chief Technical Officer
Mr. Gil Beyen BVBA
CEO & Director
ERYP stock traded closed the last session at $1.31, which is -$0.030000000000000027 or -2.325581395348839% lower than its previous close of $1.305. ERYP's current trading price is 36.46% lower than its 52-week high of $6.59 where as its distance from 52-week low of 0.96% is -80.12%.
Number of ERYP employees currently stands at -. ERYP operates from 60 Avenue Rockefeller, Lyon 69008, France.
Official Webiste of $ERYP is: https://www.erytech.com
ERYP could be contacted at ERYP operates from 60 Avenue Rockefeller, Lyon 69008, France, or at phone #33 4 78 74 44 38 and can also be accessed through its website.
ERYP stock volume for the day was 2,754 shares while in the previous session number of ERYP shares traded was 58,105 . The average number of ERYP shares traded daily for last 3 months was 13.1 Thousands.
The percentage change in ERYP stock occurred in the recent session was -2.325581395348839% while the dollar amount for the price change in ERYP stock was -$0.030000000000000027.
In the recent session, the day high for ERYP stock was $1.472 while the low for ERYP stock touched on the day was $1.29.
The market value of ERYP currently stands at 41.84 Million with its latest stock price at $1.26 and 31.02 Million of its shares outstanding.